ProVerum

Motivation

Trinity College Dublin (TCD), together with spin-off ProVerum Medical, has developed a novel, minimally invasive treatment for patients with benign prostatic hyperplasia (BPH). BPH is one of the most common conditions in men. It affects about half of all men age 60 and older. Worldwide, there are 400 million men with BPH and over 1 million associated surgical procedures per year. The BPH market is worth approximately $30 billion. There is a clear clinical need for less invasive procedures.

Project description

The solution developed by TCD and ProVerum has great potential: it offers patients relief from BPH symptoms through a minimally invasive, rapid procedure. Unlike previous stent-based approaches, BHP therapy is more effective and also has no adverse sexual effects.

Our services

Fraunhofer IMW and Genesis Biomed are collaborative partners in the project. Together, they are developing the commercialization prospects of the clinical procedure. The Leipzig research team is conducting the market analysis in Germany, including interviews with experts, in order to better assess the clinical requirements for alternative therapy approaches based on stents.